Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Level 5 - mechanism / opinion, no new human data
Clinical practice guideline based on expert panel consensus
PubMed 33406487 · doi:10.6004/jnccn.2021.0001
What was done
The National Comprehensive Cancer Network (NCCN) updated its clinical practice guidelines (Version 2.2021) addressing genetic and familial high-risk assessment, genetic testing, counseling, and risk management strategies. This publication focuses specifically on cancer risk assessment and management for individuals with pathogenic or likely pathogenic variants linked to BRCA1/2-related hereditary breast and ovarian cancer syndrome and Li-Fraumeni syndrome.
What was found
The abstract reports no numerical data, effect estimates, or statistical measures. It summarizes that BRCA1/2 pathogenic or likely pathogenic variant carriers face elevated risks for breast, ovarian, prostate, and pancreatic cancers, warranting intensive screening and prevention strategies. It also describes Li-Fraumeni syndrome as a highly penetrant condition conferring high lifetime risk for soft tissue sarcomas, osteosarcomas, premenopausal breast cancer, colon cancer, gastric cancer, adrenocortical carcinoma, and brain tumors.
Why it matters
These updated guidelines provide standardized clinical guidance on genetic assessment, testing thresholds, and risk-management protocols for high-penetrance cancer predisposition syndromes.
Limits
The abstract contains no empirical research data, sample size figures, or statistical estimates. It reflects consensus recommendations rather than primary experimental or observational trial results.
Cited by
- supports BRCA mutations account for only a small minority of overall cancers, but confer a very high individual lifetime cancer risk to carriers.